These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21191114)

  • 1. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
    Schmidt C
    J Natl Cancer Inst; 2011 Jan; 103(2):87-9. PubMed ID: 21191114
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
    Moelans CB; van Diest PJ
    J Natl Cancer Inst; 2011 Apr; 103(8):698-9. PubMed ID: 21406657
    [No Abstract]   [Full Text] [Related]  

  • 3. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
    Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L
    Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693
    [No Abstract]   [Full Text] [Related]  

  • 4. Experts debate value of HER2 testing methods.
    Nelson NJ
    J Natl Cancer Inst; 2000 Feb; 92(4):292-4. PubMed ID: 10675369
    [No Abstract]   [Full Text] [Related]  

  • 5. HER2 Intermediate Breast Cancers.
    Jensen KC; Nielsen TO; Gilks CB; West RB
    Am J Surg Pathol; 2009 Nov; 33(11):1739; author reply 1739-40. PubMed ID: 19745698
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies.
    Arena V; Pennacchia I; Monego G; Carbone A; Capelli A
    J Clin Oncol; 2010 Feb; 28(5):e83-4; author reply e85-8. PubMed ID: 20065180
    [No Abstract]   [Full Text] [Related]  

  • 7. HER2 testing and correlation with efficacy of trastuzumab therapy.
    Fornier M; Risio M; Van Poznak C; Seidman A
    Oncology (Williston Park); 2002 Oct; 16(10):1340-8, 1351-2; discussion 1352, 1355-8. PubMed ID: 12435204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
    Blank PR; Schwenkglenks M; Moch H; Szucs TD
    Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inconsistency of HER2 test raises questions.
    Tuma RS
    J Natl Cancer Inst; 2007 Jul; 99(14):1064-5. PubMed ID: 17623788
    [No Abstract]   [Full Text] [Related]  

  • 10. [Her2/neu receptor: one of the basic factors rendering tailored therapy feasible in breast cancer patients].
    Kulka J
    Orv Hetil; 2005 Apr; 146(17):785-90. PubMed ID: 17918634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of HER2 status in breast cancer].
    Penault-Llorca F; Cayre A
    Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab administration associated with change in HER2 status.
    Dawood S; Resetkova E; Gonzalez-Angulo AM
    Clin Breast Cancer; 2008 Aug; 8(4):366-9. PubMed ID: 18757266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.
    Wilking U; Karlsson E; Skoog L; Hatschek T; Lidbrink E; Elmberger G; Johansson H; Lindström L; Bergh J
    Breast Cancer Res Treat; 2011 Jan; 125(2):553-61. PubMed ID: 20628810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: HER2 testing in the real world.
    Vincent-Salomon A; MacGrogan G; Couturier J; Arnould L; Mathoulin-Pélissier S;
    J Natl Cancer Inst; 2003 Apr; 95(8):628; author reply 628-9. PubMed ID: 12697858
    [No Abstract]   [Full Text] [Related]  

  • 15. Saving lives with accurate HER2 testing.
    Ross JS
    Am J Clin Pathol; 2010 Aug; 134(2):183-4. PubMed ID: 20660318
    [No Abstract]   [Full Text] [Related]  

  • 16. Information for patients. HER2: what you need to know.
    Oncology (Williston Park); 2009 Jul; 23(8 Suppl):48a-48b. PubMed ID: 19860043
    [No Abstract]   [Full Text] [Related]  

  • 17. Tissue microarray technology in breast cancer HER2 diagnostics.
    Egervari K; Szollosi Z; Nemes Z
    Pathol Res Pract; 2007; 203(3):169-77. PubMed ID: 17292562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between overexpression of HER-2/neu protein and prognosis in epithelial ovarian cancer].
    Sasaki N; Takano M; Kudou K; Kita T; Kikuchi Y
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():582-6. PubMed ID: 15535312
    [No Abstract]   [Full Text] [Related]  

  • 19. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.
    Grimm EE; Schmidt RA; Swanson PE; Dintzis SM; Allison KH
    Am J Clin Pathol; 2010 Aug; 134(2):284-92. PubMed ID: 20660333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of HER2 testing: caught between a rock and a hard place.
    Schnitt SJ; Jacobs TW
    Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.